Get started
Author

Kaiming Sun

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2019 · Antonio González-Martín, Bhavana Pothuri, et al. · New England Journal of Medicine · 2,270
PDF
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
2006 · Tong Ihn Lee, Richard G. Jenner, et al. · Cell · 2,268
PDF
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
2019 · Kathleen N Moore, Angeles Alvarez Secord, et al. · The Lancet Oncology · 535
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
2019 · Zebin Wang, Kaiming Sun, et al. · Scientific Reports · 252
PDF
The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes
2009 · Richard G. Jenner, Michael J. Townsend, et al. · Proceedings of the National Academy of Sciences · 251
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
2018 · Kaiming Sun, Keith Mikule, et al. · Oncotarget · 174
PDF
Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
2016 · Kaiming Sun, Ruzanna Atoyan, et al. · Molecular Cancer Therapeutics · 139
Saccharomyces forkhead protein Fkh1 regulates donor preference during mating-type switching through the recombination enhancer
2002 · Kaiming Sun, Eric Coı̈c, et al. · Genes & Development · 52
PDF
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
2020 · Antonio González-Martín, Bhavana Pothuri, et al. · Obstetrical & Gynecological Survey · 46
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2024 · Patricia J. Keller, Elizabeth J. Adams, et al. · Cancer Research · 33
Cell Cycle-Dependent Regulation of Saccharomyces cerevisiae Donor Preference during Mating-Type Switching by SBF (Swi4/Swi6) and Fkh1
2006 · Eric Coïc, Kaiming Sun, et al. · Molecular and Cellular Biology · 27
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
2019 · Maria J Sambade, Amanda E D Van Swearingen, et al. · Neuro-Oncology Advances · 22
PDF
Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.
2021 · Nehal J. Lakhani, Martin Gutierrez, et al. · Journal of Clinical Oncology · 15
Abstract 1724: Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
2018 · Sarah Wang, Kaiming Sun, et al. · Cancer Research · 7
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
2019 · Mansoor Raza Mirza, Bin Feng, et al. · Journal of Clinical Oncology · 5
The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL
2016 · Kaiming Sun, Ruzanna Atoyan, et al. · Blood · 5
A Saccharomyces servazzii clone homologous to Saccharomyces cerevisiae chromosome III spanning KAR4, ARS 304 and SPB1 lacks the recombination enhancer but contains an unknown ORF
2001 · Zhiqi Zhou, Kaiming Sun, et al. · Yeast · 5
Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma
2015 · Anas Younes, Jesus G. Berdeja, et al. · Blood · 4
Abstract A102: A comparative pharmacokinetic-pharmacodynamic-treatment study of PARP inhibitors demonstrates favorable properties for niraparib activity in preclinical tumor models
2018 · Kaiming Sun, Grace Poon, et al. · Molecular Cancer Therapeutics · 3
Abstract 2952: Predicting concentration of PARP inhibitors in human tumor tissue using PBPK modeling
2019 · Rachel H. Rose, Kaiming Sun, et al. · Cancer Research · 2
Abstract 2126: Therapeutic potential of CPI-0209
2021 · Rentian Wu, Feng Zhao, et al. · Cancer Research · 1
Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS
2019 · Kathleen Moore, Angeles Secord, et al. · Clinical Cancer Research · 1
Abstract 2952: Predicting concentration of PARP inhibitors in human tumor tissue using PBPK modeling
2019 · Rachel H. Rose, Kaiming Sun, et al. · Experimental and Molecular Therapeutics · 1
Abstract 2813: Efficacy and pharmacokinetics of niraparib in BRCA-mutant and wild-type intracranial triple negative breast cancer murine models
2018 · Maria Sambade, Amanda Van Swearingen, et al. · Cancer Research · 1
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
2026 · Patricia J. Keller, Elizabeth J. Adams, et al.
Works count: 84
Citation count: 6,119
H-index: 13
I10-index: 13
Year
Topic
Type